Studie SHIFT (the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial) a její přínos pro léčbu srdečního selhání
| Title in English | The SHIFT study (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial) and its benefit for heart failure treatment |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Intervenční a akutní kardiologie |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | heart failure; ivabradine; heart rate |
| Description | The SHIFT study compared the effect of ivabradine with that of placebo in 6,558 patients with heart failure of ischaemic as well as nonischaemic aetiology, functional classification NYHA II-IV, with a resting heart rate above 70 bpm who received an optimal treatment for heart failure, including a maximum tolerated dose of beta blockers. The study has shown a significant reduction in the risk of the primary endpoint of cardiovascular mortality and hospitalization for heart failure by 18% in the group treated with ivabradine. Also, there was a decrease in the risk of death from heart failure by 26% in the active treated group. The decrease in hospitalization rate for heart failure was similar. Ivabradine was well tolerated with minimal side effects. |
| Related projects: |